




PHARMACEUTICAL 2023

OptiNose Inc.
Rank 357 of 446





RealRate

PHARMACEUTICAL 2023

OptiNose Inc.
Rank 357 of 446



The relative strengths and weaknesses of OptiNose Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OptiNose Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 37% points. The greatest weakness of OptiNose Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -100%, being 143% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	140,484
Cost of Goods Sold	9,263
Intangible Assets	0
Liabilities, Current	178,730
Liabilities, Non-Current	626
Other Assets	2,943
Other Compr. Net Income	-3.0
Other Expenses	16,843
Other Liabilities	21,490
Other Net Income	-698
Other Revenues	74,880
Property and Equipment	795
Research and Development	15,260
Selling, General and Administrative Expense	107,649

Output Variable	Value in 1000 USD
Assets	144,222
Liabilities	200,846
Expenses	149,015
Revenues	74,880
Stockholders Equity	-56,624
Net Income	-74,833
Comprehensive Net Income	-74,834
Economic Capital Ratio	-100%